Other Species / Isoforms
  MARK3 (human)      LTP 

LTP (Low Throughput Papers) : The number of records in which this modification site was determined using methods other than discovery mass spectrometry.

 HTP 

HTP (High Throughput Papers): The number of records in which this modification site was assigned using ONLY proteomic discovery mass spectrometry.

 
T3-p
_____MStRtPLPTV
0 1
MARK3 (human) _____MStRtPLPTV T3-p
MARK3 iso3 (human) _____MSTRTPLPTV T3
MARK3 iso6 (human) _____MSTRTPLPTV T3
MARK3 iso7 (human) _____MSTRTPLPTV T3
MARK3 (mouse) _____MSTRTPLPTV T3
MARK3 (rat) _____MSTRTPLPTV T3
T5-p
___MStRtPLPTVNE
0 1
MARK3 (human) ___MStRtPLPTVNE T5-p
MARK3 iso3 (human) ___MSTRTPLPTVNE T5
MARK3 iso6 (human) ___MSTRTPLPTVNE T5
MARK3 iso7 (human) ___MSTRTPLPTVNE T5
MARK3 (mouse) ___MSTRTPLPTVNE T5
MARK3 (rat) ___MSTRTPLPTVNE T5
S42-p
SGARCRNsIAsCADE
Upstream
0 9
Treatment
  • Y27632
MARK3 (human) SGARCRNsIAsCADE S42-p
MARK3 iso3 (human) SGARCRNsIAsCADE S42-p
MARK3 iso6 (human) SGARCRNSIASCADE S42
MARK3 iso7 (human) SGARCRNSIASCADE S42
MARK3 (mouse) SGARCRNsIAsCADE S42-p
MARK3 (rat) SGARCRNSIASCADE S42
S45-p
RCRNsIAsCADEQPH
0 8
MARK3 (human) RCRNsIAsCADEQPH S45-p
MARK3 iso3 (human) RCRNsIAsCADEQPH S45-p
MARK3 iso6 (human) RCRNSIASCADEQPH S45
MARK3 iso7 (human) RCRNSIASCADEQPH S45
MARK3 (mouse) RCRNsIAsCADEQPH S45-p
MARK3 (rat) RCRNSIASCADEQPH S45
T61-p
GNYRLLKtIGKGNFA
0 16
MARK3 (human) GNYRLLKtIGKGNFA T61-p
MARK3 iso3 (human) GNYRLLKtIGKGNFA T61-p
MARK3 iso6 (human) GNYRLLKTIGKGNFA T61
MARK3 iso7 (human) GNYRLLKTIGKGNFA T61
MARK3 (mouse) GNYRLLKtIGKGNFA T61-p
MARK3 (rat) GNYRLLKTIGKGNFA T61
T90
AIKIIDKTQLNPTSL
1 0
MARK3 (human) AIKIIDKTQLNPTSL T90
MARK3 iso3 (human) AIKIIDKtQLNPtsL T90-p
MARK3 iso6 (human) AIKIIDKTQLNPTSL T90
MARK3 iso7 (human) AIKIIDKTQLNPTSL T90
MARK3 (mouse) AIKIIDKTQLNPTSL T90
MARK3 (rat) AIKIIDKTQLNPTSL T90
T95
DKTQLNPTSLQKLFR
1 0
MARK3 (human) DKTQLNPTSLQKLFR T95
MARK3 iso3 (human) DKtQLNPtsLQKLFR T95-p
MARK3 iso6 (human) DKTQLNPTSLQKLFR T95
MARK3 iso7 (human) DKTQLNPTSLQKLFR T95
MARK3 (mouse) DKTQLNPTSLQKLFR T95
MARK3 (rat) DKTQLNPTSLQKLFR T95
S96
KTQLNPTSLQKLFRE
1 0
MARK3 (human) KTQLNPTSLQKLFRE S96
MARK3 iso3 (human) KtQLNPtsLQKLFRE S96-p
MARK3 iso6 (human) KTQLNPTSLQKLFRE S96
MARK3 iso7 (human) KTQLNPTSLQKLFRE S96
MARK3 (mouse) KTQLNPTSLQKLFRE S96
MARK3 (rat) KTQLNPTSLQKLFRE S96
S164-p
SKFRQIVsAVQYCHQ
0 2
MARK3 (human) SKFRQIVsAVQYCHQ S164-p
MARK3 iso3 (human) SKFRQIVSAVQYCHQ S164
MARK3 iso6 (human) SKFRQIVSAVQYCHQ S164
MARK3 iso7 (human) LMFTFIVSAVQYCHQ S187
MARK3 (mouse) AKFRQIVsAVQYCHQ S164-p
MARK3 (rat) AKFRQIVSAVQYCHQ S164
T211-p
TVGGKLDtFCGsPPY
Upstream
Downstream
3 77
MARK3 (human)
T211-p
MARK3 (mouse)
T211-p
MARK3 (rat)
T211-p
Effects on Modified Protein
  • enzymatic activity, induced
Kinase, in vitro:
  • LKB1 (human)
Putative in vivo kinases:
  • LKB1 (human)
Regulatory protein:
  • LKB1 (human)
Treatment
  • Y27632
MARK3 (human) TVGGKLDtFCGsPPY T211-p
MARK3 iso3 (human) TVGGKLDtFCGSPPY T211-p
MARK3 iso6 (human) TVGGKLDTFCGSPPY T211
MARK3 iso7 (human) TVGGKLDTFCGSPPY T234
MARK3 (mouse) TVGSKLDtFCGsPPY T211-p
MARK3 (rat) TVGSKLDtFCGSPPY T211-p
S215-p
KLDtFCGsPPYAAPE
Upstream
Downstream
2 23
Effects on Modified Protein
  • enzymatic activity, induced
Kinase, in vitro:
  • LKB1 (human)
Regulatory protein:
  • LKB1 (human)
MARK3 (human) KLDtFCGsPPYAAPE S215-p
MARK3 iso3 (human) KLDtFCGSPPYAAPE S215
MARK3 iso6 (human) KLDTFCGSPPYAAPE S215
MARK3 iso7 (human) KLDTFCGSPPYAAPE S238
MARK3 (mouse) KLDtFCGsPPYAAPE S215-p
MARK3 (rat) KLDtFCGSPPYAAPE S215
K294-ub
FLVLNPIkRGTLEQI
0 5
MARK3 (human) FLVLNPIkRGTLEQI K294-ub
MARK3 iso3 (human) FLVLNPIKRGTLEQI K294
MARK3 iso6 (human) FLVLNPIKRGTLEQI K294
MARK3 iso7 (human) FLVLNPIKRGTLEQI K317
MARK3 (mouse) FLVLNPVKRGTLEQI K294
MARK3 (rat) FLVLNPVKRGTLEQI K294
K317-ub
GHEEDELkPFVEPEL
0 1
MARK3 (human) GHEEDELkPFVEPEL K317-ub
MARK3 iso3 (human) GHEEDELKPFVEPEL K317
MARK3 iso6 (human) GHEEDELKPFVEPEL K317
MARK3 iso7 (human) GHEEDELKPFVEPEL K340
MARK3 (mouse) GHEEDELKPFVEPEL K317
MARK3 (rat) GHEEEELKPFVEPEL K317
K330-ub
ELDISDQkRIDIMVG
0 2
MARK3 (human) ELDISDQkRIDIMVG K330-ub
MARK3 iso3 (human) ELDISDQKRIDIMVG K330
MARK3 iso6 (human) ELDISDQKRIDIMVG K330
MARK3 iso7 (human) ELDISDQKRIDIMVG K353
MARK3 (mouse) ELDISDQKRIDIMVG K330
MARK3 (rat) ELDISDQKRIDIMVG K330
Y340-p
DIMVGMGysQEEIQE
0 1
MARK3 (human) DIMVGMGysQEEIQE Y340-p
MARK3 iso3 (human) DIMVGMGYSQEEIQE Y340
MARK3 iso6 (human) DIMVGMGYSQEEIQE Y340
MARK3 iso7 (human) DIMVGMGYSQEEIQE Y363
MARK3 (mouse) DIMVGMGYSQEEIQE Y340
MARK3 (rat) DIMVGMGYSQEEIQE Y340
S341-p
IMVGMGysQEEIQES
0 2
MARK3 (human) IMVGMGysQEEIQES S341-p
MARK3 iso3 (human) IMVGMGYSQEEIQES S341
MARK3 iso6 (human) IMVGMGYSQEEIQES S341
MARK3 iso7 (human) IMVGMGYSQEEIQES S364
MARK3 (mouse) IMVGMGYSQEEIQES S341
MARK3 (rat) IMVGMGYSQEEIQES S341
K367-ub
TYLLLGRkSSELDAs
0 1
MARK3 (human) TYLLLGRkSSELDAs K367-ub
MARK3 iso3 (human) TYLLLGRKSSELDAS K367
MARK3 iso6 (human) TYLLLGRKSSEVRPS K367
MARK3 iso7 (human) TYLLLGRKSSEVRPS K390
MARK3 (mouse) TYLLLGRKsAELDAs K367
MARK3 (rat) TYLLLGRKSAELDAs K367
S368
YLLLGRkSSELDAsD
0 1
MARK3 (human) YLLLGRkSSELDAsD S368
MARK3 iso3 (human) YLLLGRKSSELDASD S368
MARK3 iso6 (human) YLLLGRKSSEVRPSS S368
MARK3 iso7 (human) YLLLGRKSSEVRPSS S391
MARK3 (mouse) YLLLGRKsAELDAsD S368-p
MARK3 (rat) YLLLGRKSAELDAsD S368
S374-p
kSSELDAsDsssssN
0 9
MARK3 (human) kSSELDAsDsssssN S374-p
MARK3 iso3 (human) KSSELDASDSSsSSN S374
MARK3 iso6 (human) gap -
MARK3 iso7 (human) gap -
MARK3 (mouse) KsAELDAsDSssssN S374-p
MARK3 (rat) KSAELDAsDSsSSsN S374-p
S376-p
SELDAsDsssssNLs
0 2
MARK3 (human) SELDAsDsssssNLs S376-p
MARK3 iso3 (human) SELDASDSSsSSNLS S376
MARK3 iso6 (human) gap -
MARK3 iso7 (human) gap -
MARK3 (mouse) AELDAsDSssssNLs S376
MARK3 (rat) AELDAsDSsSSsNLs S376
S377-p
ELDAsDsssssNLsL
0 5
MARK3 (human) ELDAsDsssssNLsL S377-p
MARK3 iso3 (human) ELDASDSSsSSNLSL S377
MARK3 iso6 (human) gap -
MARK3 iso7 (human) gap -
MARK3 (mouse) ELDAsDSssssNLsL S377-p
MARK3 (rat) ELDAsDSsSSsNLsL S377-p
S378-p
LDAsDsssssNLsLA
0 8
MARK3 (human) LDAsDsssssNLsLA S378-p
MARK3 iso3 (human) LDASDSSsSSNLSLA S378-p
MARK3 iso6 (human) gap -
MARK3 iso7 (human) gap -
MARK3 (mouse) LDAsDSssssNLsLA S378-p
MARK3 (rat) LDAsDSsSSsNLsLA S378
S379-p
DAsDsssssNLsLAK
0 5
MARK3 (human) DAsDsssssNLsLAK S379-p
MARK3 iso3 (human) DASDSSsSSNLSLAK S379
MARK3 iso6 (human) gap -
MARK3 iso7 (human) gap -
MARK3 (mouse) DAsDSssssNLsLAK S379-p
MARK3 (rat) DAsDSsSSsNLsLAK S379
S380-p
AsDsssssNLsLAKV
0 10
MARK3 (human) AsDsssssNLsLAKV S380-p
MARK3 iso3 (human) ASDSSsSSNLSLAKV S380
MARK3 iso6 (human) gap -
MARK3 iso7 (human) gap -
MARK3 (mouse) AsDSssssNLsLAKV S380-p
MARK3 (rat) AsDSsSSsNLsLAKV S380-p
S383-p
sssssNLsLAKVRPS
Upstream
0 10
Treatment
  • MLN8054
MARK3 (human) sssssNLsLAKVRPS S383-p
MARK3 iso3 (human) SSsSSNLSLAKVRPS S383
MARK3 iso6 (human) gap -
MARK3 iso7 (human) gap -
MARK3 (mouse) SssssNLsLAKVRPN S383-p
MARK3 (rat) SsSSsNLsLAKVRPS S383-p
S391
LAKVRPSSDLNNstG
0 15
MARK3 (human) LAKVRPSSDLNNstG S391
MARK3 iso3 (human) LAKVRPSSDLNNsTG S391
MARK3 iso6 (human) SSEVRPSSDLNNSTG S375
MARK3 iso7 (human) SSEVRPSSDLNNSTG S398
MARK3 (mouse) LAKVRPNsDLsNsTG S391-p
MARK3 (rat) LAKVRPSSDLSNSTG S391
N394
VRPSSDLNNstGQsP
0 3
MARK3 (human) VRPSSDLNNstGQsP N394
MARK3 iso3 (human) VRPSSDLNNsTGQsP N394
MARK3 iso6 (human) VRPSSDLNNSTGQsP N378
MARK3 iso7 (human) VRPSSDLNNSTGQSP N401
MARK3 (mouse) VRPNsDLsNsTGQsP S394-p
MARK3 (rat) VRPSSDLSNSTGQSP S394
S396-p
PSSDLNNstGQsPHH
0 3
MARK3 (human) PSSDLNNstGQsPHH S396-p
MARK3 iso3 (human) PSSDLNNsTGQsPHH S396-p
MARK3 iso6 (human) PSSDLNNSTGQsPHH S380
MARK3 iso7 (human) PSSDLNNSTGQSPHH S403
MARK3 (mouse) PNsDLsNsTGQsPHH S396-p
MARK3 (rat) PSSDLSNSTGQSPHH S396
T397-p
SSDLNNstGQsPHHK
0 1
MARK3 (human) SSDLNNstGQsPHHK T397-p
MARK3 iso3 (human) SSDLNNsTGQsPHHK T397
MARK3 iso6 (human) SSDLNNSTGQsPHHK T381
MARK3 iso7 (human) SSDLNNSTGQSPHHK T404
MARK3 (mouse) NsDLsNsTGQsPHHK T397
MARK3 (rat) SSDLSNSTGQSPHHK T397
S400-p
LNNstGQsPHHKVQR
Upstream
0 27
Treatment
  • nocodazole
MARK3 (human) LNNstGQsPHHKVQR S400-p
MARK3 iso3 (human) LNNsTGQsPHHKVQR S400-p
MARK3 iso6 (human) LNNSTGQsPHHKVQR S384-p
MARK3 iso7 (human) LNNSTGQSPHHKVQR S407
MARK3 (mouse) LsNsTGQsPHHKGQR S400-p
MARK3 (rat) LSNSTGQSPHHKGQR S400
F410
under review
0 1
MARK3 (human) under review F410
MARK3 iso3 (human) under review F410
MARK3 iso6 (human) under review F394
MARK3 iso7 (human) HKVQRSVSSSQKQRR S417
MARK3 (mouse) HKGQRSVsSSQKQRR S410-p
MARK3 (rat) HKGQRSVSSSQKQRR S410
Y418-p
SSQKQRRysDHAGPA
0 3
MARK3 (human) SSQKQRRysDHAGPA Y418-p
MARK3 iso3 (human) SSQKQRRYsDHAGPA Y418
MARK3 iso6 (human) SSQKQRRYSDHAGPA Y402
MARK3 iso7 (human) SSQKQRRYSDHAGPA Y425
MARK3 (mouse) SSQKQRRysDHAGPA Y418-p
MARK3 (rat) SSQKQRRYsDHAGPA Y418
S419-p
SQKQRRysDHAGPAI
Upstream
0 39
Treatment
  • BI_4834
  • metastatic potential
MARK3 (human) SQKQRRysDHAGPAI S419-p
MARK3 iso3 (human) SQKQRRYsDHAGPAI S419-p
MARK3 iso6 (human) SQKQRRYSDHAGPAI S403
MARK3 iso7 (human) SQKQRRYSDHAGPAI S426
MARK3 (mouse) SQKQRRysDHAGPAI S419-p
MARK3 (rat) SQKQRRYsDHAGPAI S419-p
Y432-p
AIPSVVAyPKRSQtS
0 3
MARK3 (human) AIPSVVAyPKRSQtS Y432-p
MARK3 iso3 (human) AIPSVVAYPKRSQTS Y432
MARK3 iso6 (human) AIPSVVAYPKRSQTS Y416
MARK3 iso7 (human) AIPSVVAYPKRSQTS Y439
MARK3 (mouse) AIPSVVAYPKRSQtS Y432
MARK3 (rat) AIPSVVAYPKRSQTS Y432
T438-p
AyPKRSQtSTADSDL
0 7
MARK3 (human) AyPKRSQtSTADSDL T438-p
MARK3 iso3 (human) AYPKRSQTSTADSDL T438
MARK3 iso6 (human) AYPKRSQTSTADSDL T422
MARK3 iso7 (human) AYPKRSQTSTADSDL T445
MARK3 (mouse) AYPKRSQtSTADSDL T438-p
MARK3 (rat) AYPKRSQTSTADSDL T438
S455-p
DGISSRKssGsAVGG
0 2
MARK3 (human) DGISSRKssGsAVGG S455-p
MARK3 iso3 (human) DGISSRKSSGSAVGG S455
MARK3 iso6 (human) DGISSRKSSGSAVGG S439
MARK3 iso7 (human) DGISSRKSSGSAVGG S462
MARK3 (mouse) DGIPSRKSsSSAVGG S455
MARK3 (rat) DGVPSRKSGSSAVGG S455
S456-p
GISSRKssGsAVGGK
0 2
MARK3 (human) GISSRKssGsAVGGK S456-p
MARK3 iso3 (human) GISSRKSSGSAVGGK S456
MARK3 iso6 (human) GISSRKSSGSAVGGK S440
MARK3 iso7 (human) GISSRKSSGSAVGGK S463
MARK3 (mouse) GIPSRKSsSSAVGGK S456-p
MARK3 (rat) GVPSRKSGSSAVGGK G456
S458-p
SSRKssGsAVGGKGI
0 1
MARK3 (human) SSRKssGsAVGGKGI S458-p
MARK3 iso3 (human) SSRKSSGSAVGGKGI S458
MARK3 iso6 (human) SSRKSSGSAVGGKGI S442
MARK3 iso7 (human) SSRKSSGSAVGGKGI S465
MARK3 (mouse) PSRKSsSSAVGGKGI S458
MARK3 (rat) PSRKSGSSAVGGKGI S458
S469-p
GKGIAPAsPMLGNAs
Upstream
0 50
Treatment
  • ischemia
  • LRRK2-IN-1
  • osimertinib
  • rociletinib
MARK3 (human) GKGIAPAsPMLGNAs S469-p
MARK3 iso3 (human) GKGIAPAsPMLGNAS S469-p
MARK3 iso6 (human) GKGIAPASPMLGNAS S453
MARK3 iso7 (human) GKGIAPASPMLGNAS S476
MARK3 (mouse) GKGIAPAsPMLGNAG S469-p
MARK3 (rat) GKGIAPAsPMLGNAS S469-p
S476-p
sPMLGNAsNPNKADI
0 2
MARK3 (human) sPMLGNAsNPNKADI S476-p
MARK3 iso3 (human) sPMLGNASNPNKADI S476
MARK3 iso6 (human) SPMLGNASNPNKADI S460
MARK3 iso7 (human) SPMLGNASNPNKADI S483
MARK3 (mouse) sPMLGNAGNPNKADI G476
MARK3 (rat) sPMLGNASNPNKADI S476
S489-p
DIPERKKsstVPsSN
Upstream
0 6
Treatment
  • wortmannin
MARK3 (human) DIPERKKsstVPsSN S489-p
MARK3 iso3 (human) DIPERKKSstVPSSN S489
MARK3 iso6 (human) DIPERKKSsTVPSSN S473
MARK3 iso7 (human) DIPERKKSSTVPSSN S496
MARK3 (mouse) DIPERKKsPAVPsSN S489-p
MARK3 (rat) DIPERKKSPAVPSSN S489
S490-p
IPERKKsstVPsSNT
0 7
MARK3 (human) IPERKKsstVPsSNT S490-p
MARK3 iso3 (human) IPERKKSstVPSSNT S490-p
MARK3 iso6 (human) IPERKKSsTVPSSNT S474-p
MARK3 iso7 (human) IPERKKSSTVPSSNT S497
MARK3 (mouse) IPERKKsPAVPsSNT P490
MARK3 (rat) IPERKKSPAVPSSNA P490
T491-p
PERKKsstVPsSNTA
0 9
MARK3 (human) PERKKsstVPsSNTA T491-p
MARK3 iso3 (human) PERKKSstVPSSNTA T491-p
MARK3 iso6 (human) PERKKSsTVPSSNTA T475
MARK3 iso7 (human) PERKKSSTVPSSNTA T498
MARK3 (mouse) PERKKsPAVPsSNTA A491
MARK3 (rat) PERKKSPAVPSSNAA A491
S494-p
KKsstVPsSNTAsGG
0 2
MARK3 (human) KKsstVPsSNTAsGG S494-p
MARK3 iso3 (human) KKSstVPSSNTASGG S494
MARK3 iso6 (human) KKSsTVPSSNTASGG S478
MARK3 iso7 (human) KKSSTVPSSNTASGG S501
MARK3 (mouse) KKsPAVPsSNTASGG S494-p
MARK3 (rat) KKSPAVPSSNAASGG S494
S499-p
VPsSNTAsGGMtRRN
0 3
MARK3 (human) VPsSNTAsGGMtRRN S499-p
MARK3 iso3 (human) VPSSNTASGGMTRRN S499
MARK3 iso6 (human) VPSSNTASGGMTRRN S483
MARK3 iso7 (human) VPSSNTASGGMTRRN S506
MARK3 (mouse) VPsSNTASGGMtRRN S499
MARK3 (rat) VPSSNAASGGMTRRN S499
T503-p
NTAsGGMtRRNtyVC
0 5
MARK3 (human) NTAsGGMtRRNtyVC T503-p
MARK3 iso3 (human) NTASGGMTRRNtyVC T503
MARK3 iso6 (human) NTASGGMTRRNtyVC T487
MARK3 iso7 (human) NTASGGMTRRNTYVC T510
MARK3 (mouse) NTASGGMtRRNtyVC T503-p
MARK3 (rat) NAASGGMTRRNtYVC T503
T507-p
GGMtRRNtyVCsERT
Upstream
1 323
Kinase, in vitro:
  • PKACA (human)
Putative in vivo kinases:
  • PKACA (human)
Treatment
  • BI_4834
  • gefitinib
  • rapamycin
MARK3 (human) GGMtRRNtyVCsERT T507-p
MARK3 iso3 (human) GGMTRRNtyVCSERT T507-p
MARK3 iso6 (human) GGMTRRNtyVCSERT T491-p
MARK3 iso7 (human) GGMTRRNTYVCSERT T514
MARK3 (mouse) GGMtRRNtyVCSERC T507-p
MARK3 (rat) GGMTRRNtYVCSERC T507-p
Y508-p
GMtRRNtyVCsERTT
0 45
MARK3 (human) GMtRRNtyVCsERTT Y508-p
MARK3 iso3 (human) GMTRRNtyVCSERTT Y508-p
MARK3 iso6 (human) GMTRRNtyVCSERTT Y492-p
MARK3 iso7 (human) GMTRRNTYVCSERTT Y515
MARK3 (mouse) GMtRRNtyVCSERCA Y508-p
MARK3 (rat) GMTRRNtYVCSERCA Y508
S511-p
RRNtyVCsERTTADR
0 1
MARK3 (human) RRNtyVCsERTTADR S511-p
MARK3 iso3 (human) RRNtyVCSERTTADR S511
MARK3 iso6 (human) RRNtyVCSERTTADR S495
MARK3 iso7 (human) RRNTYVCSERTTADR S518
MARK3 (mouse) RRNtyVCSERCAADR S511
MARK3 (rat) RRNtYVCSERCAADR S511
S520-p
RTTADRHsVIQNGKE
0 2
MARK3 (human) RTTADRHsVIQNGKE S520-p
MARK3 iso3 (human) RTTADRHSVIQNGKE S520
MARK3 iso6 (human) RTTADRHSVIQNGKE S504
MARK3 iso7 (human) RTTADRHSVIQNGKE S527
MARK3 (mouse) RCAADRHsVIQNGKE S520-p
MARK3 (rat) RCAADRHSVIQNGKE S520
S529
IQNGKENSTIPDQRt
0 1
MARK3 (human) IQNGKENSTIPDQRt S529
MARK3 iso3 (human) IQNGKENSTIPDQRt S529
MARK3 iso6 (human) IQNGKENSTIPDQRT S513
MARK3 iso7 (human) IQNGKENSTIPDQRT S536
MARK3 (mouse) IQNGKENsAIPDERT S529-p
MARK3 (rat) IQNGKESSLTEVFAY S529
T536-p
STIPDQRtPVAstHs
Upstream
0 8
Treatment
  • vemurafenib
MARK3 (human) STIPDQRtPVAstHs T536-p
MARK3 iso3 (human) STIPDQRtPVAStHs T536-p
MARK3 iso6 (human) STIPDQRTPVASTHS T520
MARK3 iso7 (human) STIPDQRTPVASTHS T543
MARK3 (mouse) sAIPDERTPVAstHs T536
MARK3 (rat) ITTPDQRTPVASTHS T589
S540-p
DQRtPVAstHsIssA
Upstream
0 27
Treatment
  • EGF
MARK3 (human) DQRtPVAstHsIssA S540-p
MARK3 iso3 (human) DQRtPVAStHsISSA S540
MARK3 iso6 (human) DQRTPVASTHSISSA S524
MARK3 iso7 (human) DQRTPVASTHSISSA S547
MARK3 (mouse) DERTPVAstHsIsSA S540-p
MARK3 (rat) DQRTPVASTHSISSA S593
T541-p
QRtPVAstHsIssAA
0 10
MARK3 (human) QRtPVAstHsIssAA T541-p
MARK3 iso3 (human) QRtPVAStHsISSAA T541-p
MARK3 iso6 (human) QRTPVASTHSISSAA T525
MARK3 iso7 (human) QRTPVASTHSISSAA T548
MARK3 (mouse) ERTPVAstHsIsSAT T541-p
MARK3 (rat) QRTPVASTHSISSAT T594
S543-p
tPVAstHsIssAAtP
0 22
MARK3 (human) tPVAstHsIssAAtP S543-p
MARK3 iso3 (human) tPVAStHsISSAAtP S543-p
MARK3 iso6 (human) TPVASTHSISSAATP S527
MARK3 iso7 (human) TPVASTHSISSAATP S550
MARK3 (mouse) TPVAstHsIsSATtP S543-p
MARK3 (rat) TPVASTHSISSATTP S596
S545-p
VAstHsIssAAtPDR
0 3
MARK3 (human) VAstHsIssAAtPDR S545-p
MARK3 iso3 (human) VAStHsISSAAtPDR S545
MARK3 iso6 (human) VASTHSISSAATPDR S529
MARK3 iso7 (human) VASTHSISSAATPDR S552
MARK3 (mouse) VAstHsIsSATtPDR S545-p
MARK3 (rat) VASTHSISSATTPDR S598
S546-p
AstHsIssAAtPDRI
0 1
MARK3 (human) AstHsIssAAtPDRI S546-p
MARK3 iso3 (human) AStHsISSAAtPDRI S546
MARK3 iso6 (human) ASTHSISSAATPDRI S530
MARK3 iso7 (human) ASTHSISSAATPDRI S553
MARK3 (mouse) AstHsIsSATtPDRI S546
MARK3 (rat) ASTHSISSATTPDRI S599
T549-p
HsIssAAtPDRIRFP
Upstream
0 15
Treatment
  • MG132_withdrawal
  • MLN8054
  • nocodazole
  • thymidine
MARK3 (human) HsIssAAtPDRIRFP T549-p
MARK3 iso3 (human) HsISSAAtPDRIRFP T549-p
MARK3 iso6 (human) HSISSAATPDRIRFP T533
MARK3 iso7 (human) HSISSAATPDRIRFP T556
MARK3 (mouse) HsIsSATtPDRIRFP T549-p
MARK3 (rat) HSISSATTPDRIRFP T602
S563
PRGTASRStFHGQPR
0 1
MARK3 (human) PRGTASRStFHGQPR S563
MARK3 iso3 (human) PRGTASRStFHGQPR S563
MARK3 iso6 (human) PRGTASRSTFHGQPR S547
MARK3 iso7 (human) PRGTASRSTFHGQPR S570
MARK3 (mouse) PRGTASRstFHGQPR S563-p
MARK3 (rat) PRGTASRSTFHGQPR S616
T564-p
RGTASRStFHGQPRE
Upstream
1 6
Kinase, in vitro:
  • PKCZ (human)
Putative in vivo kinases:
  • PKCI (human)
  • PKCZ (human)
MARK3 (human) RGTASRStFHGQPRE T564-p
MARK3 iso3 (human) RGTASRStFHGQPRE T564-p
MARK3 iso6 (human) RGTASRSTFHGQPRE T548
MARK3 iso7 (human) RGTASRSTFHGQPRE T571
MARK3 (mouse) RGTASRstFHGQPRE T564-p
MARK3 (rat) RGTASRSTFHGQPRE T617
T574-p
GQPRERRtAtyNGPP
0 1
MARK3 (human) GQPRERRtAtyNGPP T574-p
MARK3 iso3 (human) GQPRERRTAtYNGPP T574
MARK3 iso6 (human) GQPRERRTATYNGPP T558
MARK3 iso7 (human) GQPRERRTATYNGPP T581
MARK3 (mouse) GQPRERRTAtYNGPP T574
MARK3 (rat) GQPRERRTATYNGPP T627
T576-p
PRERRtAtyNGPPAs
0 8
MARK3 (human) PRERRtAtyNGPPAs T576-p
MARK3 iso3 (human) PRERRTAtYNGPPAs T576-p
MARK3 iso6 (human) PRERRTATYNGPPAS T560
MARK3 iso7 (human) PRERRTATYNGPPAS T583
MARK3 (mouse) PRERRTAtYNGPPAs T576-p
MARK3 (rat) PRERRTATYNGPPAS T629
Y577-p
RERRtAtyNGPPAsP
0 10
MARK3 (human) RERRtAtyNGPPAsP Y577-p
MARK3 iso3 (human) RERRTAtYNGPPAsP Y577
MARK3 iso6 (human) RERRTATYNGPPASP Y561
MARK3 iso7 (human) RERRTATYNGPPASP Y584
MARK3 (mouse) RERRTAtYNGPPAsP Y577
MARK3 (rat) RERRTATYNGPPASP Y630
S583-p
tyNGPPAsPsLsHEA
Upstream
0 33
Treatment
  • CXCL12
MARK3 (human) tyNGPPAsPsLsHEA S583-p
MARK3 iso3 (human) tYNGPPAsPSLSHEA S583-p
MARK3 iso6 (human) TYNGPPASPSLSHEA S567
MARK3 iso7 (human) TYNGPPASPSLSHEA S590
MARK3 (mouse) tYNGPPAsPSLsHEA S583-p
MARK3 (rat) TYNGPPASPSLSHEA S636
S585-p
NGPPAsPsLsHEAtP
0 7
MARK3 (human) NGPPAsPsLsHEAtP S585-p
MARK3 iso3 (human) NGPPAsPSLSHEATP S585
MARK3 iso6 (human) NGPPASPSLSHEATP S569
MARK3 iso7 (human) NGPPASPSLSHEATP S592
MARK3 (mouse) NGPPAsPSLsHEATP S585
MARK3 (rat) NGPPASPSLSHEATP S638
S587-p
PPAsPsLsHEAtPLs
0 10
MARK3 (human) PPAsPsLsHEAtPLs S587-p
MARK3 iso3 (human) PPAsPSLSHEATPLS S587
MARK3 iso6 (human) PPASPSLSHEATPLS S571
MARK3 iso7 (human) PPASPSLSHEATPLS S594
MARK3 (mouse) PPAsPSLsHEATPLS S587-p
MARK3 (rat) PPASPSLSHEATPLS S640
T591-p
PsLsHEAtPLsQtRs
Upstream
0 3
Treatment
  • EGF
MARK3 (human) PsLsHEAtPLsQtRs T591-p
MARK3 iso3 (human) PSLSHEATPLSQTRs T591
MARK3 iso6 (human) PSLSHEATPLSQTRS T575
MARK3 iso7 (human) PSLSHEATPLSQTRS T598
MARK3 (mouse) PSLsHEATPLSQTRs T591
MARK3 (rat) PSLSHEATPLSQTRS T644
S594-p
sHEAtPLsQtRsrGs
0 1
MARK3 (human) sHEAtPLsQtRsrGs S594-p
MARK3 iso3 (human) SHEATPLSQTRsRGs S594
MARK3 iso6 (human) SHEATPLSQTRSRGS S578
MARK3 iso7 (human) SHEATPLSQTRSRGS S601
MARK3 (mouse) sHEATPLSQTRsrGs S594
MARK3 (rat) SHEATPLSQTRSRGS S647
T596-p
EAtPLsQtRsrGsTN
0 1
MARK3 (human) EAtPLsQtRsrGsTN T596-p
MARK3 iso3 (human) EATPLSQTRsRGstN T596
MARK3 iso6 (human) EATPLSQTRSRGSTN T580
MARK3 iso7 (human) EATPLSQTRSRGSTN T603
MARK3 (mouse) EATPLSQTRsrGsTN T596
MARK3 (rat) EATPLSQTRSRGSTN T649
S598-p
tPLsQtRsrGsTNLF
1 5
MARK3 (human) tPLsQtRsrGsTNLF S598-p
MARK3 iso3 (human) TPLSQTRsRGstNLF S598-p
MARK3 iso6 (human) TPLSQTRSRGSTNLF S582
MARK3 iso7 (human) TPLSQTRSRGSTNLF S605
MARK3 (mouse) TPLSQTRsrGsTNLF S598-p
MARK3 (rat) TPLSQTRSRGSTNLF S651
R599-m1
PLsQtRsrGsTNLFS
0 3
MARK3 (human) PLsQtRsrGsTNLFS R599-m1
MARK3 iso3 (human) PLSQTRsRGstNLFs R599
MARK3 iso6 (human) PLSQTRSRGSTNLFS R583
MARK3 iso7 (human) PLSQTRSRGSTNLFS R606
MARK3 (mouse) PLSQTRsrGsTNLFS R599-m1
MARK3 (rat) PLSQTRSRGSTNLFS R652
S601-p
sQtRsrGsTNLFSKL
1 25
MARK3 (human) sQtRsrGsTNLFSKL S601-p
MARK3 iso3 (human) SQTRsRGstNLFsKL S601-p
MARK3 iso6 (human) SQTRSRGSTNLFSKL S585
MARK3 iso7 (human) SQTRSRGSTNLFSKL S608
MARK3 (mouse) SQTRsrGsTNLFSKL S601-p
MARK3 (rat) SQTRSRGSTNLFSKL S654
T602
QtRsrGsTNLFSKLT
1 0
MARK3 (human) QtRsrGsTNLFSKLT T602
MARK3 iso3 (human) QTRsRGstNLFsKLT T602-p
MARK3 iso6 (human) QTRSRGSTNLFSKLT T586
MARK3 iso7 (human) QTRSRGSTNLFSKLT T609
MARK3 (mouse) QTRsrGsTNLFSKLT T602
MARK3 (rat) QTRSRGSTNLFSKLT T655
S606
rGsTNLFSKLTSKLT
1 0
MARK3 (human) rGsTNLFSKLTSKLT S606
MARK3 iso3 (human) RGstNLFsKLTSKLT S606-p
MARK3 iso6 (human) RGSTNLFSKLTSKLT S590
MARK3 iso7 (human) RGSTNLFSKLTSKLT S613
MARK3 (mouse) rGsTNLFSKLTSKLT S606
MARK3 (rat) RGSTNLFSKLTSKLT S659
S618-p
KLTRRNMsFRFIKRL
Upstream
0 2
Treatment
  • ischemia
MARK3 (human) KLTRRNMsFRFIKRL S618-p
MARK3 iso3 (human) gap -